A Summary of the Previous Studies on Hyperammonemia due
to the Carbamoyl Phosphate
Student’s name
Institution Affiliation
Date
Introduction
Carbamoyl phosphate synthesis 1 is a recessive urea cycle inborn error that responsible
for causing high levels of ammonia in the blood (hyperammonemia). In this
condition, the urea cycle cannot proceed normally due to low levels or absence
of carbamoyl phosphate synthetase 1 enzyme. Consequently, nitrogen gets
accumulated in the blood in toxic ammonia (Yefimenko et al., 2005). Previous
studies have dealt with the analysis of CPS1 mutation that affects a certain
domain of a person’s CPS1. The Paper will summarize the previous studies on a
high level of ammonia in the blood due to the compound carbonyl phosphate in
newborns due to inbreeding, adults, and the appearance of symptoms and the
nutritional treatment used for them in hospitals.
In exploring the effects of the mutations, a novel system is used in the producing and the creation of genetic mutation of recombinant CPS1(Yank et al., 2017). The clinic observation has led the testing in CPS of the CPSI Q262P mutation, which decreases the activity of the enzyme disturbing the ammonia tunnel .cDNA3 sequencing has helped identify mutation in patients resulting in a report on the identification of missense mutations. However, the CPS1 gene is large, and the missense mutation’s identification does not demonstrate the mutation’s because reasons vitro expression
system using site-direction mutagenesis is used during the standard testing
procedure. (Alfadhel et al., 2016).
Clinical
results were that the mutant enzyme undergoes isolation. Its stability is
affected, the mutations reduced carbamoyl phosphate synthesis, the individual
mutations cause specific derangements like the abolishment of synthesis of
carbamoyl phosphate from either ammonia
or glutamine without an abolishment of reactions of ATP synthesis and ATPase by A126M
mutation.
Newborns due to inbreeding
After a few days, newborns with hyperammonemia develop
high hyperammonemic encephalopathy rapidly. High mortality rates occur if the
patients are treated late or left untreated due to irreversible brain edema.
The newborns are found to demonstrate hyperammonemia, including vomiting,
unusual sleepiness, lethargy, poor feeding, weak muscle tone, and seizures, and
if untreated, it can lead to coma and even death (Yank et al., 2017). With
effective treatment also, the disorder may cause some neurological
abnormalities like intellectual disability and developmental delays. The
severity of these abnormalities is mostly in newborns who have stayed in coma
for a prolonged period.
Adults and the Appearance of Symptoms Suddenly
Hyperammonemic episodes may recur in patients in
catabolic situations such as during fasting, fever, or viral illness. Studies
have proven that there is no age limit for these episodes’ reoccurrence or the
risk of hyperammonemia. Adults who survive the above-mentioned newborn period
may experience the appearance of these symptoms suddenly if their diet is not
carefully observed or even due to stress and other infections. Exposure to
certain medications like steroids or valproate can cause the onset of these
symptoms later in life (Yefimenko et al., 2005). Individuals may experience
breathing problems, seizures, vomiting, ataxia, protein aversion, confusion,
hallucinations, low body temperature, and intellectual disability due to mental
or psychomotor retardation, which may vary from mild to severe. Coma and death
may also occur.
The Nutritional Treatment Used for Them in Hospitals
When a person is diagnosed with hyperammonemia, protein
intake is immediately terminated, and additional high calories are given. As
soon as the level of ammonia reaches 80-100 L, proteins should be reintroduced
to maximize the intake of calories. High intake of calories can be achieved by
IV lipid emulsion and IV dextrose ten percent giving and or more with respect
to the age and its glucose requirement. Dietary restrictions to the individuals
are observed to limit the amount of intake of protein. Restriction of protein
in the diet is aimed to provide limited amounts of threonine, methionine,
valine, and isoleucine and add fatty acids. Children with this disorder are
restricted to a high calorie, a low-protein diet supplemented by amino acids
whose concentrations are monitored depending on age, compliance, and metabolic
stability. (Alfadhel et al., 2016).
Conclusion
Acute hyperammonemia can be caused by the laxity of
individuals to discover its symptoms. Clinicians are faced with the challenge
of selecting an appropriate management protocol for the disease due to its
rarity. Due to this disease’s dangerous effects, doctors should ensure early
treatment as soon as a patient is diagnosed with it.
References
Alfadhel, M., Al Mutairi, F., Makhseed, N., Al Jasmi, F.,
Al-Thihli, K., Al-Jishi, E., … & Ben-Omran, T. (2016). Guidelines for
acute management of hyperammonemia in the Middle East region. Therapeutics and clinical risk management, 12, 479.
Conditions, G. (2020). Carbamoyl phosphate synthetase I
deficiency: MedlinePlus Genetics. Retrieved 27 October 2020, from https://medlineplus.gov/genetics/condition/carbamoyl-phosphate-synthetase-i-deficiency/
Yang, X., Shi, J., Lei, H., Xia, B., & Mu, D. (2017).
Neonatal-onset carbamoyl phosphate synthetase I deficiency: A case report. Medicine, 96(26).
Yefimenko, I., Fresquet, V., Marco-Marín, C., Rubio, V.,
& Cervera, J. (2005). Understanding carbamoyl phosphate synthetase
deficiency: impact of clinical mutations on enzyme functionality. Journal of molecular biology, 349(1), 127-141.